Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure
-
Published:2016-08-01
Issue:10
Volume:60
Page:6398-6401
-
ISSN:0066-4804
-
Container-title:Antimicrobial Agents and Chemotherapy
-
language:en
-
Short-container-title:Antimicrob. Agents Chemother.
Author:
Gonzalez-Serna A.,Genebat M.,De Luna-Romero M.,Tarancon-Diez L.,Dominguez-Molina B.,Pacheco Y. M.,Muñoz-Fernández M. A.,Leal M.,Ruiz-Mateos E.
Abstract
ABSTRACTTROCAI is a phenotypic tropism test developed using the virological response to a short-term exposure to maraviroc monotherapy (Maraviroc Clinical Test [MCT]). It was found that with TROCAI, a cutoff of <0.5% of dual/mixed viruses was needed to predict R5 HIV tropism. Here, we have validated TROCAI, using this cutoff, in a new cohort of 42 patients, finding a very high concordance between TROCAI and MCT (98%), and a good concordance (71 to 87%) with other genotypic/phenotypic methods.
Funder
Fondo de Investigaciones Sanitarias
MINECO | Instituto de Salud Carlos III (ISCIII)
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference20 articles.
1. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity;Antimicrob Agents Chemother,2005
2. Maraviroc: a review of its use in HIV infection and beyond;Drug Des Devel Ther,2015
3. An enhanced-sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies;J Viral Entry,2009
4. Discordance rates between Trofile test and short-term virological response to maraviroc;Antiviral Res,2011
5. Genotypic determination of HIV tropism–clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists;AIDS Rev,2010